Eloxx Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2022. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating drug candidates for rare diseases and cancers. ELX-02, its lead clinical candidate, is being studied in cystic fibrosis patients with nonsense mutations. The company reported no product or service revenue.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.9 million | $4.1 million; up 94% |
| General and administrative expense | $3.1 million | $4.3 million; down 30% |
| Total operating expenses | $11.0 million | $8.4 million; up 30% |
| Operating loss | $11.0 million | $8.4 million |
| Other expense, net | $0.7 million | $0.3 million |
| Net loss | $11.6 million | $8.7 million; loss increased 34% |
| Net loss per share | $0.13 | $0.22; lower loss per share reflects a substantially larger weighted-average share count |
| Cash used in operating activities | $9.5 million | $7.7 million |
Margins are not meaningful because the company had no revenue. At March 31, cash and cash equivalents were $39.8 million, with restricted cash of $0.3 million. Current assets were $42.1 million and current liabilities were $19.2 million. The company had a $249.9 million accumulated deficit.
Outstanding Hercules term-loan principal was $12.5 million; the balance sheet reported $12.1 million of long-term debt, including the final fee, with no current portion. The loan carries a floating rate subject to a 9.5% floor; its effective rate was 15.25% at quarter-end. The company was compliant with covenants at March 31, but must maintain a specified minimum qualified cash balance.
Material changes versus the prior comparable period
- R&D costs rose $3.8 million, principally from higher preclinical activity, clinical-trial costs, personnel, and overhead following the expansion of programs.
- G&A fell $1.3 million, mainly due to lower personnel, stock-based compensation, professional fees, and overhead.
- Net loss widened by $2.9 million. Other expense increased, including a $0.3 million charge for the fair-value change in Cystic Fibrosis Foundation (CFF) embedded derivative liabilities and higher Hercules-loan interest expense.
- Cash used in operations increased by $1.8 million. Cash, cash equivalents, and restricted cash declined $2.5 million during the quarter, after $7.0 million of CFF funding was received.
Outlook, commentary, and risks
- Management stated that March 31 cash of $39.8 million is not sufficient to fund current and planned operations for at least 12 months after the filing, and concluded that substantial doubt exists about the company’s ability to continue as a going concern without additional funding. No committed external funding source was identified.
- The March 2022 CFF agreement provides up to $15.9 million for ELX-02 cystic-fibrosis Phase 2 development: $7.0 million was received upfront, and up to $8.9 million remains contingent on milestones. The funding is recorded as an advance, not revenue; future sales may trigger royalties, and certain disposition events may trigger additional payments.
- Management expected to present data from the first four ELX-02 Phase 2 treatment arms in Q4 2022 and planned to file an IND in 2022 for RDEB/JEB programs. These are forward-looking plans, not guaranteed outcomes. No formal financial guidance was provided.
- ELX-02’s development depends on clinical safety, efficacy, patient enrollment, and regulatory outcomes. The filing notes renal toxicities in preclinical animals at doses above those expected in clinical trials, and warns that COVID-19 may disrupt trials and operations.
- The company had received a Nasdaq notice for trading below the $1.00 minimum bid price and had until July 5, 2022 to regain compliance. It also disclosed that Form S-3 limits then restricted ATM sales to approximately $13.0 million.
- Failure to raise capital could require reduced or deferred spending, workforce reductions, or curtailment of development programs. Covenant breaches could permit the lender to accelerate repayment. The company reported no material pending legal proceedings.
Key facts investors should verify
- Whether subsequent financing, partnering, or milestone funding improved the stated cash runway and going-concern position.
- Final ELX-02 Phase 2 results, trial timing, enrollment, safety findings, and any regulatory or program changes.
- Whether Nasdaq minimum-bid compliance was regained and how much, if any, was raised under the ATM program.
- Hercules loan covenant headroom, availability of undrawn tranches, and the terms and conditions attached to future funding.
- Potential CFF royalty or disposition payments and their implications for future economics.